This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Merck Looks Like a Relative Bargain

Stocks in this article: MRK JNJ PFE BMY GSK

NEW YORK (TheStreet) -- With shares of Johnson & Johnson (JNJ), Pfizer (PFE) and Bristol-Myers Squibb (BMY) all trading at near 52-week highs, there aren't many bargains left in the Big Pharma space. While I do believe Merck's (MRK) pipeline struggles and expiring patents are valid concerns, the valuation has nonetheless become enticing, even if the expected returns might be low.

Before we dive into Merck's recent results, there's a reason why the company hasn't been invited to the Street's yearlong "drug party." While Merck does have -- what I believe to be -- an underrated portfolio of effective drugs, not all of them are doing equal work. Instead, over the past couple of quarters, the company has relied primarily on Singulair, its blockbuster once-a-day asthma drug, which at one point generated $5.5 billion in annual revenue.

Unfortunately, during that span, worldwide sales of Singulair have sputtered. What's more, as competition for Singulair has increased, cheaper-priced generic alternatives to some of Merck's other top-selling drugs, like Propecia and Clarinex, have been under attack due mostly to expiring patents, which opened the floodgates to copycat versions.

Smelling Merck's blood, rivals like Pfizer and GlaxoSmithKline (GSK) have positioned themselves to exploit the weakness and steal share. Even so, I believe if Merck's management holds firm to its promise of delivering near-term growth through licensing deals and/or acquisitions, these shares may be undervalued to their long-term potential. But if Merck's recent earnings serve as an indication, it's going to take some time.

Unlike most, I tend to look at Merck's results -- as underwhelming as they may appear -- with more of a "glass half full" view. While it's true that third-quarter revenues were down 4% year-over-year to $11 billion, I see it as a 7% improvement from the 11% decline in the July quarter. Likewise, when breaking down the company's segmental performance, I noticed a similar pattern.

Pharmaceutical sales were down 4% to $9.5 billion, which was significantly impaired by a 53% decline in sales for Singulair. This, however, is not a surprise. As I've noted, the drug, whose patent expired last year has been on a consistent decline. What was a surprise, however, was the sequential improvement in overall pharmaceutical performance, which posted a 12% decline in the July quarter. Here, too, management posted an 8% improvement.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs